ClinicalTrials.Veeva

Menu
U

Urologicum Duisburg | Duisburg, Germany

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Abiraterone Acetate
TAR-200
Docetaxel
Androgen
Erdafitinib
Enzalutamide
Apalutamide
Darolutamide
Prednisone Versus Abiraterone Acetate
Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 22 total trials

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine cal...

Enrolling
Prostatic Neoplasms
Prostate Cancer
Drug: Prednisone
Drug: Ifinatamab deruxtecan

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Niraparib
Drug: Prednisone

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Prednisone
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abirater...

Enrolling
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms
Drug: Opevesostat
Drug: Dexamethasone

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig...

Enrolling
Metastatic Castration-resistant Prostate Neoplasms
Biological: Pasritamig
Other: Placebo

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the...

Enrolling
Prostatic Neoplasms, Castration-Resistant
Drug: Docetaxel
Drug: Prednisone

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: TAR-200
Biological: Cetrelimab

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Active, not recruiting
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

The purpose of this clinical phase 3 randomized trial is to compare two different dosing schedules of Docetaxel in combination with ADT and Darolutam...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Drug: Standard Darolutamide
Drug: Standard ADT (androgen deprivation therapy)

The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metasta...

Active, not recruiting
Prostatic Neoplasms
Other: Standard of care
Drug: Apalutamide 60Mg Tab

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumo...

Enrolling
Superficial Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drug: EG-70 (phase 2) Master Protocol
Drug: Surfactant Bladder Pre-Rinse and EG-70 (Substudy)

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and e...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Erdafitinib Intravesical Delivery System

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemi...

Active, not recruiting
Prostate Cancer Recurrent
Biological: RV001V
Other: Placebo

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participa...

Enrolling
Metastatic Urothelial Cancer
Drug: Cisplatin
Drug: Zimberelimab

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
Bayer logo
Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
Q
R
E
J

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems